Showing 3801-3810 of 6035 results for "".
- Genentech/Roche Complete Enrollment in Archway Phase 3 Study of the Port Delivery System with Ranibizumab in Wet AMDhttps://modernod.com/news/genentech-roche-complete-enrollment-in-archway-phase-3-study-of-the-port-delivery-system-with-ranibizumab-in-wet-amd/2476737/Genentech and Roche have completed patient enrollment in the phase 3 Archway (
- Market Scope: Booming Demand, Surgical Planning Integration Drive Growth in Ophthalmic Diagnostic Markethttps://modernod.com/news/market-scope-booming-demand-surgical-planning-integration-drive-growth-in-ophthalmic-diagnostic-market/2476723/Market Scope estimates that the ophthalmic diagnostic equipment market will total $3.2 billion in 2019, and the firm expects it to increase to $3.8 billion in 2024—for a compound annual growth rate of 3.9 percent. Contributing factors include a rising global population, with an expanding elderly
- One Week Left to Submit Nominations for OWL Awardshttps://modernod.com/news/one-week-left-to-submit-nominations-for-owl-awards/2476721/OWL is accepting nominations for the
- SIFI Announces Expansion in the French Market With Acquisition of Dacudoses and Novoptinehttps://modernod.com/news/sifi-announces-expansion-in-the-french-market-with-acquisition-of-dacudoses-and-novoptine/2479574/Italian ophthalmic company SIFI has announced the acquisition of Dacudoses and Novoptine antiseptic brands in France from Laboratoire Gifrer Barbezat. Terms of the deal were not disclosed. Dacudoses is the leading reimbursed RX brand of the French ophthalmic antiseptic segment, pres
- Pre-Pilot Clinical Trial from Ocutrx Vision Technologies Yields Exciting Results for Patients with AMDhttps://modernod.com/news/pre-patient-trial-from-ocutrx-vision-technologies-yields-exciting-results-for-patients-with-amd/2476659/Ocutrx Vision Technologies announced the results of the first pre-pilot clinical trial for the company’s Oculenz AR glasses. In the single arm crossover study of subjects with advanced macular degeneration, the Oculenz AR glasses significantly improved the ability of subjects to read small letter
- Allegro Ophthalmics Announces Positive Topline Results of Phase 2 Study Evaluating Risuteganib in Patients with Intermediate Dry AMDhttps://modernod.com/news/allegro-ophthalmics-announces-positive-topline-results-of-phase-2-study-evaluating-risuteganib-in-patients-with-intermediate-dry-amd/2476627/Allegro Ophthalmics announced positive topline results of its phase 2 study of risuteganib (Luminate) for the treatment of intermediate dry age-related macular degeneration (AMD). The clinical trial met its primary endpoint with 48 percent of patients in the risuteganib arm gaining ≥ 8 letters of
- Earlier Detection of Diabetic Retinopathy with Smartphone AIhttps://modernod.com/news/earlier-detection-of-diabetic-retinopathy-with-smartphone-ai/2476559/A novel pairing of two technologies may offer a solution for better screening for diabetic ret
- Thomas Walters, MD, Presents Update on Nicox’s NCX 470 Phase 2 Clinical Study in Podium Presentation at ASCRS 2019https://modernod.com/news/thomas-walters-md-presents-update-on-nicoxs-ncx-470-phase-2-clinical-study-in-podium-presentation-at-ascrs-2019/2476555/Nicox SA announced that ophthalmology key opinion leader and clinical investigator in the ongoing NCX 470 phase 2 clinical study, Thomas Walters, MD, delivered a podium presentation at the annual ASCRS 2019 meeting in San Diego updating on the progress of the NCX 470 phase 2 clinical study in pat
- Johnson & Johnson Vision Showcases the Rising Burden of Myopia, New Contact Lens and Surgical Technologies at ARVOhttps://modernod.com/news/johnson-johnson-vision-showcases-the-rising-burden-of-myopia-new-contact-lens-and-surgical-technologies-at-arvo/2476549/Johnson & Johnson Vision showcased new research abstracts covering topics across a range of eye health needs at the Association for Research in Vision and Ophthalmology annual meeting (ARVO) in Vancouver, Canada, April 28-May 2, 2019. Presentations included the first predictive model for dire
- Verseon Presents Oral Drug Candidate for Diabetic Eye Diseasehttps://modernod.com/news/verseon-presents-oral-drug-candidate-for-diabetic-eye-disease/2476516/Verseon presented promising preclinical efficacy data for the first development candidate for clinical trials in their diabetic eye disease program at this week’s ARVO 2019 annual meeting in Vancouver. This new drug candidate for oral dosing could lead to the first real alternative to eye injecti